Fig 1: Further verification of the potential therapeutic. Line chart(a) and the high-content imaging(b) illustrate decreased cell viability in A549 after transfection with si-DARS2 and si-COX5B. (c) The representative IHC staining image of low and high expression levels of DARS2 and COX5B in LUAD tumor samples. (d) The Unsupervised univariate analysis using Kaplan-Meier survival analysis of patients with lung adenocarcinoma in our hospital showed that patients with high expression of DARS2 or COX5B had shorter OS and were associated with poor prognosis.
Fig 2: The hub gene identification and prognostic validation. The Venn plot(a) showed the identification of the two hub genes. The pan-cancer dot plot identified the DARS2(b) and COX5B(c) expression profiles across all tumor samples and normal tissues. The violin plot showed the correlation between clinical stage and the expression level of DARS2(d) and COX5B(e). KM overall survival analysis of TCGA-LUAD tumor samples with high or low DARS2(f) and COX5B(g) expression. The effect of siRNA to knockdown DARS2 and COX5B mRNA levels in A549 and H358 cell lines was measured by RT–qPCR(h).
Supplier Page from Abcam for Anti-COX5B antibody [16H12H9]